394 related articles for article (PubMed ID: 18083913)
1. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
2. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
[TBL] [Abstract][Full Text] [Related]
3. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model.
Luna J; Tobe T; Mousa SA; Reilly TM; Campochiaro PA
Lab Invest; 1996 Oct; 75(4):563-73. PubMed ID: 8874387
[TBL] [Abstract][Full Text] [Related]
4. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
5. Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.
Iliaki E; Poulaki V; Mitsiades N; Mitsiades CS; Miller JW; Gragoudas ES
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4898-904. PubMed ID: 19553613
[TBL] [Abstract][Full Text] [Related]
6. Herbimycin A inhibits angiogenic activity in endothelial cells and reduces neovascularization in a rat model of retinopathy of prematurity.
McCollum GW; Rajaratnam VS; Bullard LE; Yang R; Penn JS
Exp Eye Res; 2004 May; 78(5):987-95. PubMed ID: 15051479
[TBL] [Abstract][Full Text] [Related]
7. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.
Lark MW; Stroup GB; Hwang SM; James IE; Rieman DJ; Drake FH; Bradbeer JN; Mathur A; Erhard KF; Newlander KA; Ross ST; Salyers KL; Smith BR; Miller WH; Huffman WF; Gowen M
J Pharmacol Exp Ther; 1999 Nov; 291(2):612-7. PubMed ID: 10525079
[TBL] [Abstract][Full Text] [Related]
8. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy.
Yang LP; Sun HL; Wu LM; Guo XJ; Dou HL; Tso MO; Zhao L; Li SM
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2319-27. PubMed ID: 19011009
[TBL] [Abstract][Full Text] [Related]
9. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
Kinose F; Roscilli G; Lamartina S; Anderson KD; Bonelli F; Spence SG; Ciliberto G; Vogt TF; Holder DJ; Toniatti C; Thut CJ
Mol Vis; 2005 May; 11():366-73. PubMed ID: 15951738
[TBL] [Abstract][Full Text] [Related]
11. Rosmarinic acid suppresses retinal neovascularization via cell cycle arrest with increase of p21(WAF1) expression.
Kim JH; Lee BJ; Kim JH; Yu YS; Kim MY; Kim KW
Eur J Pharmacol; 2009 Aug; 615(1-3):150-4. PubMed ID: 19470386
[TBL] [Abstract][Full Text] [Related]
12. Role of vascular endothelial growth factor in ocular angiogenesis.
Shams N; Ianchulev T
Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
[TBL] [Abstract][Full Text] [Related]
13. Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis.
You JJ; Yang CH; Huang JS; Chen MS; Yang CM
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5290-8. PubMed ID: 17962485
[TBL] [Abstract][Full Text] [Related]
14. Integrin chatter and vascular function in diabetic retinopathy.
Preissner KT; Kanse SM; Hammes HP
Horm Metab Res; 1997 Dec; 29(12):643-5. PubMed ID: 9497904
[TBL] [Abstract][Full Text] [Related]
15. Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy.
Pruneau D; Bélichard P; Sahel JA; Combal JP
Curr Opin Investig Drugs; 2010 May; 11(5):507-14. PubMed ID: 20419596
[TBL] [Abstract][Full Text] [Related]
16. Normalization of retinal vascular permeability in experimental diabetes with genistein.
Nakajima M; Cooney MJ; Tu AH; Chang KY; Cao J; Ando A; An GJ; Melia M; de Juan E
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2110-4. PubMed ID: 11481279
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.
Fu Y; Ponce ML; Thill M; Yuan P; Wang NS; Csaky KG
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5184-90. PubMed ID: 17962472
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy.
Deng G; Moran EP; Cheng R; Matlock G; Zhou K; Moran D; Chen D; Yu Q; Ma JX
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5030-5042. PubMed ID: 28979999
[TBL] [Abstract][Full Text] [Related]
20. Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes.
Zhang SX; Sima J; Wang JJ; Shao C; Fant J; Ma JX
Curr Eye Res; 2005 Aug; 30(8):681-9. PubMed ID: 16109649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
